Targeting the interplay between KLF4 and PRMT5 in carcinogenesis The goal of this project is to determine the impact of interplay between KLF4 and PRMT5 in breast carcinogenesis and anti-breast cancer therapy. Krppel-like factor 4 (KLF4) is a critical regulator of cell fate for cell division, apoptosis, and DNA damage, and plays an ambivalent role in tumorigenesis. Over 70% of human primary mammary cancers exhibit cellular accumulation of KLF4, and the impact of KLF4 on breast cancer formation has been recently indicated by the TCGA (The Cancer Genome Atlas). The most recent studies by us and others have demonstrated an oncogenic role for KLF4 in breast carcinogenesis. Nevertheless, how KLF4 is regulated and how its deregulation contributes to breast carcinogenesis remains unknown. Results from our recent purification of the KLF4 protein complex revealed that two critical enzymes, VHL and PRMT5, tightly interact with and regulate KLF4. While the ubiquitin E3 ligase VHL/VBC catalyzes KLF4 for ubiquitylation followed by degradation, we observed that methylation of KLF4 protein by PRMT5 (an arginine-based methyltransferase) results in the stabilization of KLF4 and promotion of KLF4-mediated transcription. Unexpected elevation of KLF4 levels due to enhanced KLF4 methylation counteracts KLF4 ubiquitylation, which in turn triggers tumor initiation and promotes tumor invasion. We further observed that deregulation of KLF4 methylation by aberrant PRMT5 expression impairs DNA damage checkpoint function, which could induce malignant transformation due to loss of genomic integrity. Thus, we ask if PRMT5 is a critical factor that determines the oncogenic role for KLF4 in breast carcinogenesis, and if the PRMT5-KLF4 cascade could be a novel target for breast cancer therapy. This proposal aims to determine the pathophysiological role of KLF4 methylation by PRMT5 in mammary tumorigenesis, and to further identify the clinical relevance of the KLF4-PRMT5 axis in breast cancer therapy. In this project, we plan to test the hypothesis that deregulation of KLF4 by PRMT5 promotes tumorigenesis and tumor invasion by pursuing the following specific aims: (1) to determine how methylation of KLF4 by PRMT5 regulates KLF4 protein stability and function; (2) to determine how the dysregulation of KLF4 by PRMT5 affects the self-renewal of breast cancer stem cells and promotes tumorigenesis; and (3) to determine the impact of deregulation of KLF4 by PRMT5 in breast tumor progression/invasion and validate the therapeutic intervention of our newly developed KLF4 methylation inhibitor in breast cancer treatment using murine models.

Public Health Relevance

Results from recent TCGA and pathological studies imply the oncogenic role for KLF4 in breast carcinogenesis. However, the underlying molecular mechanisms by which dysregulation of KLF4 contributes to breast tumor initiation and invasion remain unknown. This proposal focuses on discerning the interplay between two types of posttranslational modifications (ubiquitylation vs. protein methylation) in regulating KLF4 function, whose impaired regulation triggers breast tumor formation and promotes tumor invasion. Completion of this project will uncover the mitogenic role of KLF4 in breast cancer development, and could provide a new strategy for anti-breast cancer treatment by using our newly developed KLF4 inhibitor.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA202963-03
Application #
9313211
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Ault, Grace S
Project Start
2016-07-08
Project End
2021-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Zhou, Zhuan; Luo, Aiping; Shrivastava, Indira et al. (2017) Regulation of XIAP Turnover Reveals a Role for USP11 in Promotion of Tumorigenesis. EBioMedicine 15:48-61
He, Mingjing; Zhou, Zhuan; Wu, George et al. (2017) Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication. Pharmacol Ther 177:96-107
Zhou, H; Liu, Y; Zhu, R et al. (2017) FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation. Oncogene 36:3312-3321
Gao, Ying; Li, Changling; Wei, Leizhen et al. (2017) SSRP1 Cooperates with PARP and XRCC1 to Facilitate Single-Strand DNA Break Repair by Chromatin Priming. Cancer Res 77:2674-2685
Zhou, Zhuan; He, Mingjing; Shah, Anil A et al. (2016) Insights into APC/C: from cellular function to diseases and therapeutics. Cell Div 11:9
He, Mingjing; Zhou, Zhuan; Shah, Anil A et al. (2016) New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics. Cell Div 11:4
He, Mingjing; Zhou, Zhuan; Shah, Anil A et al. (2016) The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics. Cell Biosci 6:62
Lu, Songjian; Cai, Chunhui; Yan, Gonghong et al. (2016) Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations. Cancer Res 76:6785-6794